POINT Biopharma Global (NASDAQ:PNT) Trading 2.1% Higher

POINT Biopharma Global Inc. (NASDAQ:PNTGet Rating)’s share price rose 2.1% on Thursday . The stock traded as high as $9.98 and last traded at $9.95. Approximately 1,557 shares were traded during trading, a decline of 100% from the average daily volume of 449,920 shares. The stock had previously closed at $9.75.

Analyst Ratings Changes

Several research analysts have recently commented on PNT shares. Jefferies Financial Group raised POINT Biopharma Global from a “hold” rating to a “buy” rating and boosted their target price for the stock from $7.00 to $20.00 in a report on Thursday, May 26th. William Blair initiated coverage on POINT Biopharma Global in a report on Wednesday, July 6th. They issued an “outperform” rating for the company. Guggenheim began coverage on shares of POINT Biopharma Global in a report on Tuesday, August 16th. They set a “buy” rating and a $20.00 price objective on the stock. Finally, Piper Sandler dropped their target price on shares of POINT Biopharma Global from $17.00 to $14.00 and set a “na” rating for the company in a research note on Friday, May 13th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

POINT Biopharma Global Stock Performance

The company has a market capitalization of $922.88 million, a price-to-earnings ratio of -12.49 and a beta of 0.07. The business’s 50-day simple moving average is $8.17 and its 200-day simple moving average is $7.60.

Institutional Trading of POINT Biopharma Global

Institutional investors and hedge funds have recently made changes to their positions in the business. Firethorn Wealth Partners LLC raised its position in shares of POINT Biopharma Global by 6.5% in the 1st quarter. Firethorn Wealth Partners LLC now owns 33,750 shares of the company’s stock valued at $269,000 after acquiring an additional 2,050 shares during the period. California State Teachers Retirement System raised its holdings in POINT Biopharma Global by 13.2% in the first quarter. California State Teachers Retirement System now owns 34,586 shares of the company’s stock worth $276,000 after purchasing an additional 4,035 shares during the period. Sigma Planning Corp boosted its position in shares of POINT Biopharma Global by 32.4% during the second quarter. Sigma Planning Corp now owns 19,480 shares of the company’s stock worth $133,000 after purchasing an additional 4,765 shares in the last quarter. Swiss National Bank boosted its position in shares of POINT Biopharma Global by 7.3% during the first quarter. Swiss National Bank now owns 85,166 shares of the company’s stock worth $679,000 after purchasing an additional 5,800 shares in the last quarter. Finally, Claro Advisors LLC grew its holdings in shares of POINT Biopharma Global by 52.3% in the 4th quarter. Claro Advisors LLC now owns 23,300 shares of the company’s stock valued at $130,000 after buying an additional 8,000 shares during the period. Institutional investors own 53.83% of the company’s stock.

About POINT Biopharma Global

(Get Rating)

POINT Biopharma Global Inc, a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.

Featured Stories

Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.